Cargando…
MacroH2A1 Immunoexpression in Breast Cancer
MacroH2A1 has two splice isoforms, macroH2A1.1 and macroH2A1.2, that have been studied in several form of cancer. In the literature there are not many scientific papers dealing with the role of macroH2A1 in breast cancer. Breast cancer is the most frequent form of malignancy in females. It tend to m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471871/ https://www.ncbi.nlm.nih.gov/pubmed/32974186 http://dx.doi.org/10.3389/fonc.2020.01519 |
_version_ | 1783578860698206208 |
---|---|
author | Broggi, Giuseppe Filetti, Veronica Ieni, Antonio Rapisarda, Venerando Ledda, Caterina Vitale, Ermanno Varricchio, Silvia Russo, Daniela Lombardo, Claudia Tuccari, Giovanni Caltabiano, Rosario Loreto, Carla |
author_facet | Broggi, Giuseppe Filetti, Veronica Ieni, Antonio Rapisarda, Venerando Ledda, Caterina Vitale, Ermanno Varricchio, Silvia Russo, Daniela Lombardo, Claudia Tuccari, Giovanni Caltabiano, Rosario Loreto, Carla |
author_sort | Broggi, Giuseppe |
collection | PubMed |
description | MacroH2A1 has two splice isoforms, macroH2A1.1 and macroH2A1.2, that have been studied in several form of cancer. In the literature there are not many scientific papers dealing with the role of macroH2A1 in breast cancer. Breast cancer is the most frequent form of malignancy in females. It tend to metastasize to the bone in ~70% of patients. Despite treatment, new bone metastases will still occur in 30–50% of cases with advanced disease. Overall 5-year survival after the diagnosis of bone metastasis is ~20%. Osteoclasts and osteoblasts of the bone microenvironment are engaged by soluble factors released by neoplastic cells, resulting in bone matrix breakdown. This malfunction enhances the proliferation of the cancer cells, creating a vicious cycle. We investigated immunohistochemical expression of macroH2A1 in primitive breast cancer, focusing on the comparison of metastatic and non-metastatic cases. Furthermore, the immunohistochemical expression of macroH2A1 has been evaluated both in all cases of nodal metastases and in distant metastases. Our data demonstrated that macroH2A1 expression was higher expressed in metastatic breast cancer (77%) vs. non-metastatic breast cancer (32%). Also in analyzed metastases cases, a high macroH2A1 expression was detected: 85 and 80% in nodal and distant metastases cases, respectively. These results supported the fact that macroH2A1 is more highly expressed in breast cancer with worst prognosis. |
format | Online Article Text |
id | pubmed-7471871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74718712020-09-23 MacroH2A1 Immunoexpression in Breast Cancer Broggi, Giuseppe Filetti, Veronica Ieni, Antonio Rapisarda, Venerando Ledda, Caterina Vitale, Ermanno Varricchio, Silvia Russo, Daniela Lombardo, Claudia Tuccari, Giovanni Caltabiano, Rosario Loreto, Carla Front Oncol Oncology MacroH2A1 has two splice isoforms, macroH2A1.1 and macroH2A1.2, that have been studied in several form of cancer. In the literature there are not many scientific papers dealing with the role of macroH2A1 in breast cancer. Breast cancer is the most frequent form of malignancy in females. It tend to metastasize to the bone in ~70% of patients. Despite treatment, new bone metastases will still occur in 30–50% of cases with advanced disease. Overall 5-year survival after the diagnosis of bone metastasis is ~20%. Osteoclasts and osteoblasts of the bone microenvironment are engaged by soluble factors released by neoplastic cells, resulting in bone matrix breakdown. This malfunction enhances the proliferation of the cancer cells, creating a vicious cycle. We investigated immunohistochemical expression of macroH2A1 in primitive breast cancer, focusing on the comparison of metastatic and non-metastatic cases. Furthermore, the immunohistochemical expression of macroH2A1 has been evaluated both in all cases of nodal metastases and in distant metastases. Our data demonstrated that macroH2A1 expression was higher expressed in metastatic breast cancer (77%) vs. non-metastatic breast cancer (32%). Also in analyzed metastases cases, a high macroH2A1 expression was detected: 85 and 80% in nodal and distant metastases cases, respectively. These results supported the fact that macroH2A1 is more highly expressed in breast cancer with worst prognosis. Frontiers Media S.A. 2020-08-21 /pmc/articles/PMC7471871/ /pubmed/32974186 http://dx.doi.org/10.3389/fonc.2020.01519 Text en Copyright © 2020 Broggi, Filetti, Ieni, Rapisarda, Ledda, Vitale, Varricchio, Russo, Lombardo, Tuccari, Caltabiano and Loreto. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Broggi, Giuseppe Filetti, Veronica Ieni, Antonio Rapisarda, Venerando Ledda, Caterina Vitale, Ermanno Varricchio, Silvia Russo, Daniela Lombardo, Claudia Tuccari, Giovanni Caltabiano, Rosario Loreto, Carla MacroH2A1 Immunoexpression in Breast Cancer |
title | MacroH2A1 Immunoexpression in Breast Cancer |
title_full | MacroH2A1 Immunoexpression in Breast Cancer |
title_fullStr | MacroH2A1 Immunoexpression in Breast Cancer |
title_full_unstemmed | MacroH2A1 Immunoexpression in Breast Cancer |
title_short | MacroH2A1 Immunoexpression in Breast Cancer |
title_sort | macroh2a1 immunoexpression in breast cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471871/ https://www.ncbi.nlm.nih.gov/pubmed/32974186 http://dx.doi.org/10.3389/fonc.2020.01519 |
work_keys_str_mv | AT broggigiuseppe macroh2a1immunoexpressioninbreastcancer AT filettiveronica macroh2a1immunoexpressioninbreastcancer AT ieniantonio macroh2a1immunoexpressioninbreastcancer AT rapisardavenerando macroh2a1immunoexpressioninbreastcancer AT leddacaterina macroh2a1immunoexpressioninbreastcancer AT vitaleermanno macroh2a1immunoexpressioninbreastcancer AT varricchiosilvia macroh2a1immunoexpressioninbreastcancer AT russodaniela macroh2a1immunoexpressioninbreastcancer AT lombardoclaudia macroh2a1immunoexpressioninbreastcancer AT tuccarigiovanni macroh2a1immunoexpressioninbreastcancer AT caltabianorosario macroh2a1immunoexpressioninbreastcancer AT loretocarla macroh2a1immunoexpressioninbreastcancer |